A citation-based method for searching scientific literature

Zoe M Weinstein, Hyunjoong W Kim, Debbie M Cheng, Emily Quinn, David Hui, Colleen T Labelle, Mari-Lynn Drainoni, Sara S Bachman, Jeffrey H Samet. J Subst Abuse Treat 2017
Times Cited: 104







List of co-cited articles
653 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Richard P Mattick, Courtney Breen, Jo Kimber, Marina Davoli. Cochrane Database Syst Rev 2014
864
27

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Luis Sordo, Gregorio Barrio, Maria J Bravo, B Iciar Indave, Louisa Degenhardt, Lucas Wiessing, Marica Ferri, Roberto Pastor-Barriuso. BMJ 2017
809
27

Retention in medication-assisted treatment for opiate dependence: A systematic review.
Christine Timko, Nicole R Schultz, Michael A Cucciare, Lisa Vittorio, Christina Garrison-Diehn. J Addict Dis 2016
213
26

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Daniel P Alford, Colleen T LaBelle, Natalie Kretsch, Alexis Bergeron, Michael Winter, Michael Botticelli, Jeffrey H Samet. Arch Intern Med 2011
173
24

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Yih-Ing Hser, Andrew J Saxon, David Huang, Al Hasson, Christie Thomas, Maureen Hillhouse, Petra Jacobs, Cheryl Teruya, Paul McLaughlin, Katharina Wiest,[...]. Addiction 2014
244
21



Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Janet M Soeffing, L David Martin, Michael I Fingerhood, Donald R Jasinski, Darius A Rastegar. J Subst Abuse Treat 2009
104
17

Leaving buprenorphine treatment: patients' reasons for cessation of care.
Jan Gryczynski, Shannon Gwin Mitchell, Jerome H Jaffe, Kevin E O'Grady, Yngvild K Olsen, Robert P Schwartz. J Subst Abuse Treat 2014
71
21

Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Hillary Samples, Arthur Robin Williams, Mark Olfson, Stephen Crystal. J Subst Abuse Treat 2018
76
19

National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Christopher M Jones, Melinda Campopiano, Grant Baldwin, Elinore McCance-Katz. Am J Public Health 2015
442
14

Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Ajay Manhapra, Edeanya Agbese, Douglas L Leslie, Robert A Rosenheck. Psychiatr Serv 2018
41
34

Treatment utilization among persons with opioid use disorder in the United States.
Li-Tzy Wu, He Zhu, Marvin S Swartz. Drug Alcohol Depend 2016
197
14


Predictors of early dropout in outpatient buprenorphine/naloxone treatment.
David E Marcovitz, R Kathryn McHugh, Julie Volpe, Victoria Votaw, Hilary S Connery. Am J Addict 2016
45
26


Retention of patients in opioid substitution treatment: A systematic review.
Aisling Máire O'Connor, Gráinne Cousins, Louise Durand, Joe Barry, Fiona Boland. PLoS One 2020
69
17

Development of a Cascade of Care for responding to the opioid epidemic.
Arthur Robin Williams, Edward V Nunes, Adam Bisaga, Frances R Levin, Mark Olfson. Am J Drug Alcohol Abuse 2019
126
11

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Marc R Larochelle, Dana Bernson, Thomas Land, Thomas J Stopka, Na Wang, Ziming Xuan, Sarah M Bagley, Jane M Liebschutz, Alexander Y Walley. Ann Intern Med 2018
448
11

Buprenorphine Treatment Divide by Race/Ethnicity and Payment.
Pooja A Lagisetty, Ryan Ross, Amy Bohnert, Michael Clay, Donovan T Maust. JAMA Psychiatry 2019
179
11

Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
Elenore Patterson Bhatraju, Ellie Grossman, Babak Tofighi, Jennifer McNeely, Danae DiRocco, Mara Flannery, Ann Garment, Keith Goldfeld, Marc N Gourevitch, Joshua D Lee. Addict Sci Clin Pract 2017
47
21


Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Joshua D Lee, Edward V Nunes, Patricia Novo, Ken Bachrach, Genie L Bailey, Snehal Bhatt, Sarah Farkas, Marc Fishman, Phoebe Gauthier, Candace C Hodgkins,[...]. Lancet 2018
341
10


Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
David A Fiellin, Michael V Pantalon, Marek C Chawarski, Brent A Moore, Lynn E Sullivan, Patrick G O'Connor, Richard S Schottenfeld. N Engl J Med 2006
240
10

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
David A Fiellin, Richard S Schottenfeld, Christopher J Cutter, Brent A Moore, Declan T Barry, Patrick G O'Connor. JAMA Intern Med 2014
117
10

Linking patients with buprenorphine treatment in primary care: Predictors of engagement.
Claire B Simon, Judith I Tsui, Joseph O Merrill, Addy Adwell, Elsa Tamru, Jared W Klein. Drug Alcohol Depend 2017
32
31

Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
Wei-Hsuan Lo-Ciganic, Walid F Gellad, Adam J Gordon, Gerald Cochran, Michael A Zemaitis, Terri Cathers, David Kelley, Julie M Donohue. Addiction 2016
63
15

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
T V Parran, C A Adelman, B Merkin, M E Pagano, R Defranco, R A Ionescu, A G Mace. Drug Alcohol Depend 2010
86
10

Buprenorphine retention in primary care.
Michael D Stein, Patricia Cioe, Peter D Friedmann. J Gen Intern Med 2005
126
9

Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
P Todd Korthuis, Dennis McCarty, Melissa Weimer, Christina Bougatsos, Ian Blazina, Bernadette Zakher, Sara Grusing, Beth Devine, Roger Chou. Ann Intern Med 2017
160
9

Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities.
Sarah E Wakeman, Michael L Barnett. N Engl J Med 2018
88
10

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Roger D Weiss, Jennifer Sharpe Potter, David A Fiellin, Marilyn Byrne, Hilary S Connery, William Dickinson, John Gardin, Margaret L Griffin, Marc N Gourevitch, Deborah L Haller,[...]. Arch Gen Psychiatry 2011
339
9

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Sarah E Wakeman, Marc R Larochelle, Omid Ameli, Christine E Chaisson, Jeffrey Thomas McPheeters, William H Crown, Francisca Azocar, Darshak M Sanghavi. JAMA Netw Open 2020
238
9

Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Chinazo O Cunningham, Angela Giovanniello, Hillary V Kunins, Robert J Roose, Aaron D Fox, Nancy L Sohler. Am J Addict 2013
23
34

Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
David A Fiellin, Brent A Moore, Lynn E Sullivan, William C Becker, Michael V Pantalon, Marek C Chawarski, Declan T Barry, Patrick G O'Connor, Richard S Schottenfeld. Am J Addict 2008
105
8

Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.
Brandon S Bentzley, Kelly S Barth, Sudie E Back, Sarah W Book. J Subst Abuse Treat 2015
77
10

Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Scott E Hadland, J Frank Wharam, Mark A Schuster, Fang Zhang, Jeffrey H Samet, Marc R Larochelle. JAMA Pediatr 2017
144
8

Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
Natalia Shcherbakova, Gary Tereso, Jacqueline Spain, Robert J Roose. Ann Pharmacother 2018
20
40

Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population.
Brendan Saloner, Matthew Daubresse, G Caleb Alexander. Med Care 2017
49
14

Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Anne M Neumann, Richard D Blondell, Mohammadreza Azadfard, Ganon Nathan, Gregory G Homish. Addict Behav 2013
25
28


Medication-assisted therapies--tackling the opioid-overdose epidemic.
Nora D Volkow, Thomas R Frieden, Pamela S Hyde, Stephen S Cha. N Engl J Med 2014
639
7

Effect of buprenorphine dose on treatment outcome.
Ayman Fareed, Sreedevi Vayalapalli, Jennifer Casarella, Karen Drexler. J Addict Dis 2012
68
10

Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.
Rebecca L Haffajee, Amy S B Bohnert, Pooja A Lagisetty. Am J Prev Med 2018
118
7



Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Evgeny Krupitsky, Edward V Nunes, Walter Ling, Ari Illeperuma, David R Gastfriend, Bernard L Silverman. Lancet 2011
342
6


Why aren't physicians prescribing more buprenorphine?
Andrew S Huhn, Kelly E Dunn. J Subst Abuse Treat 2017
161
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.